FTH
Faeth TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The $200 million private placement and $202.8 million of cash, cash equivalents, and marketable securities as of March 31, 2026 provide funding to advance PIKTOR through endometrial and breast-cancer milestones. [#SEC-8K-2026-05-15]
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +3.1.
What can break
Binary clinical efficacy or tolerability disappointment in the Phase 2 endometrial-cancer program.
Momentum
98
Value
41
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $30.00 · Bull $50.00 · Bear $17.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-19 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $54.40
Why
Momentum98 · Δ7d +3.1
Value41 · Δ7d -0.1
SentimentN/A · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
98
40% active weight
Current posture
7d trendFlat
Δ7d
+3.1
Δ21d
-
Value
41
60% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 98.3 / Value 41.1
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$666.9M
Beta
0.28
Shares Out
25.78M
P/E (TTM) · Derived
-1.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.37
Rev YoY
-
EPS YoY
+2312.3%
Gross Margin
-
Op Margin
-
Net Debt
-$19.68M
Current Ratio
14.39
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology